CAPA Calls Cornyn/Blumenthal Bill A First Step Towards Ending Big Pharma’s Patent Abuse

Applauds Senators Cornyn and Blumenthal for their efforts to stop the major drug companies from abusing the U.S. patent system to delay or prevent patients from accessing more affordable generic alternative medications and treatments.

WASHINGTON, D.C. – The Coalition Against Patent Abuse, a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free market advocates and others released the following statement today applauding U.S. Senators Richard Blumenthal (D-CT) and John Cornyn (R-TX) for their legislation to end product-hopping and the creation of patent thickets by Big Pharma to prevent or delay competition from generic drug alternatives. The following statements are attributable to Mathew Lane, Executive Director of the Coalition Against Patent Abuse.

“CAPA applauds Senators Cornyn and Blumenthal’s bipartisan legislation for its efforts to prevent the major drug companies from gaming the U.S. patent system in pursuit of higher profits. It’s a first step in the right direction, with significant future action by Congress still needed to end Big Pharma’s blatant patent abuses that protect their monopolies at the expense of suffering patients.”

“All Americans have felt the repercussions of Big Pharma’s greed with rising health insurance premiums and out-of-pocket costs due to increasingly expensive prescription drugs without more affordable generic alternatives.”

“We thank Senators Cornyn and Blumenthal for their leadership in the face vigorous opposition from PhRMA and BIO who are determined to protect the ability of their member companies to abuse America’s patent system. There is more work to be done, and our Coalition looks forward to working with all stakeholders on this and other proposals to rein in Big Pharma’s rampant patent abuse.”

For more information, please visit